Abstract library

548 results for "GLP-1 receptor imaging".
#195 UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging using Somatostatin Receptor PET/CT
Introduction: Somatostatin receptors (SSTR) are known for an overexpression in neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Peter L, Lupp A, Schulz S, ...
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#477 Glucagon-Like Peptide 1 Receptor (GLP-1R) Imaging for the Preoperative Localization of Benign Insulinomas in 30 Patients
Introduction: Biochemical diagnosis of endogenous hyperinsulinemic hypoglycemia is straightforward. Surgical removal of an insulinoma is hampered by difficulties to localize it using conventional radiological procedures. In vitro data suggest that human insulinoma cells exhibit a high density of GLP-1R. 111In-exendin-4 is an 111In labeled GLP-1R agonist that binds with high affinity to GLP-1R and may be helpful in localizing insulinomas.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Emanuel Christ
Authors: Christ E, Forrer F, Wild D, Clerici T, ...
#772 Role of Molecular Imaging using Ga-68 Somatostatin-Receptor PET/CT in Predicting Survival after Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms
Introduction: Peptide receptor radionuclide therapy (PRRNT) is valuable for the management of metastasized and/or inoperable neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Harshad Kulkarni
#803 Analysis of Somatostatin-Receptor 2A (SSTR2A) Immunohistochemistry, RT-qPCR and In-Vivo- PET/CT Data in Patients with Pancreatic Neuroendocrine Neoplasm
Introduction: Ga-68 somatostatin receptor (SSTR) PET/CT is one of the most sensitive imaging methods for pancreatic neuroendocrine tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Daniel Kaemmerer
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#1874 Value of Somatostatin Receptor Imaging (SRI) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Base on Clinical Follow-Up
Introduction: Neuroendocrine neoplasms of the appendix are common GEP-NEN tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sonia Konsek
#2003 Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study
Introduction: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults and due to their small size difficult to localise.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Antwi Antwi
Authors: Antwi A, Heye T, Fani M, Nicolas G, ...
#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study
Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Christof Rottenburger
#563 Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors
Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum